Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion
Isak W. Tengesdal, Dinoop Ravindran Menon, Douglas G. Osborne, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 10
Open Access | Times Cited: 139

Showing 1-25 of 139 citing articles:

Macrophages as tools and targets in cancer therapy
Alberto Mantovani, Paola Allavena, Federica Marchesi, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 11, pp. 799-820
Open Access | Times Cited: 1113
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 225
The NLRP3 inflammasome: contributions to inflammation-related diseases
Ying Chen, Xingyan Ye, Germaine Escames, et al.
Cellular & Molecular Biology Letters (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 129
PMN-MDSCs accumulation induced by CXCL1 promotes CD8+ T cells exhaustion in gastric cancer
Xingyu Zhou, Deliang Fang, Haohan Liu, et al.
Cancer Letters (2022) Vol. 532, pp. 215598-215598
Closed Access | Times Cited: 86
Context-dependent functions of pattern recognition receptors in cancer
Si Ming Man, Brendan J. Jenkins
Nature reviews. Cancer (2022) Vol. 22, Iss. 7, pp. 397-413
Closed Access | Times Cited: 84
Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target
Feyza Gül Özbay Kurt, Samantha Lasser, Ihor Arkhypov, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 13
Open Access | Times Cited: 58
Involvement of inflammasomes in tumor microenvironment and tumor therapies
Ziqi Zhang, Xue Li, Yang Wang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 46
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion
Junli Lu, Yiming Luo, Dean Rao, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 41
Crosstalk between metabolism and cell death in tumorigenesis
Shichao Yang, Caden Hu, Xiaomei Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 26
NLRP3 inflammasome signalling in Alzheimer's disease
Róisín M. McManus, Eicke Latz
Neuropharmacology (2024) Vol. 252, pp. 109941-109941
Open Access | Times Cited: 25
Air pollution and skin diseases: A comprehensive evaluation of the associated mechanism
Xiaoyu Gu, Zhengrui Li, Juan Su
Ecotoxicology and Environmental Safety (2024) Vol. 278, pp. 116429-116429
Open Access | Times Cited: 18
Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy
Shuyan He, Lu Zheng, Chunjian Qi
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis
Orly Leiva, Duaa AbdelHameid, Jean M. Connors, et al.
JACC CardioOncology (2021) Vol. 3, Iss. 5, pp. 619-634
Open Access | Times Cited: 95
Tumor NLRP3-Derived IL-1β Drives the IL-6/STAT3 Axis Resulting in Sustained MDSC-Mediated Immunosuppression
Isak W. Tengesdal, Alberto Dinarello, Nicholas E. Powers, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 74
Immunotherapy of targeting MDSCs in tumor microenvironment
Hongshu Sui, Shengyi Dongye, Xiaocui Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 48
Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy
Elnaz Rouzbahani, Jamal Majidpoor, Sajad Najafi, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113906-113906
Open Access | Times Cited: 46
Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies
Ibraheem Nasir, Conor McGuinness, Ashleigh R. Poh, et al.
Trends in Immunology (2023) Vol. 44, Iss. 12, pp. 971-985
Open Access | Times Cited: 38
Divergent functions of NLRP3 inflammasomes in cancer: a review
Alireza Shadab, Mohamad Mahjoor, Mohammad Abbasi‐Kolli, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 34
Long-Read Sequencing Reveals Rapid Evolution of Immunity- and Cancer-Related Genes in Bats
Armin Scheben, O. Ramos, Melissa Kramer, et al.
Genome Biology and Evolution (2023) Vol. 15, Iss. 9
Open Access | Times Cited: 31
The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control
Jinhai Deng, Teng Pan, Zaoqu Liu, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 12, pp. 1877-1892
Open Access | Times Cited: 24
MDSC-targeting gold nanoparticles enhance PD-1 tumor immunotherapy by inhibiting NLRP3 inflammasomes
Yangyang Zhu, Pin Chen, Bochuan Hu, et al.
Biomaterials (2024) Vol. 307, pp. 122533-122533
Closed Access | Times Cited: 10
Targeted modulation of myeloid-derived suppressor cells in the tumor microenvironment: Implications for cancer therapy
Yafeng Qi, Liying Zhang, Y Q Liu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 180, pp. 117590-117590
Closed Access | Times Cited: 10
Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication
Hua Wang, Tao Wang, Shuxiang Yan, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Inflammation in cancer: therapeutic opportunities from new insights
Yifei Xie, Fangfang Liu, Yunfei Wu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy
Xueyan Li, Jiahui Zhong, Xue Deng, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top